BCRX
Price
$8.39
Change
+$0.17 (+2.07%)
Updated
Apr 25 closing price
Capitalization
1.75B
4 days until earnings call
DVAX
Price
$10.82
Change
-$0.08 (-0.73%)
Updated
Apr 25 closing price
Capitalization
1.62B
4 days until earnings call
TLSA
Price
$1.36
Change
-$0.08 (-5.56%)
Updated
Apr 25 closing price
Capitalization
158.91M
Ad is loading...

BCRX or DVAX or TLSA

Header iconBCRX vs DVAX vs TLSA Comparison
Open Charts BCRX vs DVAX vs TLSABanner chart's image
BioCryst Pharmaceuticals
Price$8.39
Change+$0.17 (+2.07%)
Volume$3.21M
Capitalization1.75B
Dynavax Technologies
Price$10.82
Change-$0.08 (-0.73%)
Volume$1.51M
Capitalization1.62B
Tiziana Life Sciences
Price$1.36
Change-$0.08 (-5.56%)
Volume$355.55K
Capitalization158.91M
BCRX vs DVAX vs TLSA Comparison Chart
Loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
Ad is loading...
COMPARISON
Comparison
Apr 27, 2025
Stock price -- (BCRX: $8.39DVAX: $10.82TLSA: $1.36)
Brand notoriety: DVAX and TLSA are not notable and BCRX is notable
BCRX and TLSA are part of the Biotechnology industry, and DVAX is in the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: BCRX: 88%, DVAX: 55%, TLSA: 43%
Market capitalization -- BCRX: $1.75B, DVAX: $1.62B, TLSA: $158.91M
$BCRX [@Biotechnology] is valued at $1.75B. $TLSA’s [@Biotechnology] market capitalization is $ $158.91M. $DVAX [@Pharmaceuticals: Other] has a market capitalization of $ $1.62B. The market cap for tickers in the [@Biotechnology] industry ranges from $ $276.16B to $ $0. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $ $77.48B to $ $0. The average market capitalization across the [@Biotechnology] industry is $ $2.14B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $ $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileDVAX’s FA Score has 0 green FA rating(s), and TLSA’s FA Score reflects 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • DVAX’s FA Score: 0 green, 5 red.
  • TLSA’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than TLSA, which in turn is a better option than DVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while DVAX’s TA Score has 4 bullish TA indicator(s), and TLSA’s TA Score reflects 5 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 4 bearish.
  • DVAX’s TA Score: 4 bullish, 5 bearish.
  • TLSA’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, BCRX is a better buy in the short-term than DVAX and TLSA.

Price Growth

BCRX (@Biotechnology) experienced а +13.38% price change this week, while DVAX (@Pharmaceuticals: Other) price change was +4.95% , and TLSA (@Biotechnology) price fluctuated +27.10% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.19%. For the same industry, the average monthly price growth was -3.08%, and the average quarterly price growth was -10.41%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +5.53%. For the same industry, the average monthly price growth was -0.55%, and the average quarterly price growth was -7.74%.

Reported Earning Dates

BCRX is expected to report earnings on Jul 31, 2025.

DVAX is expected to report earnings on Jul 31, 2025.

TLSA is expected to report earnings on Dec 28, 2022.

Industries' Descriptions

@Biotechnology (+8.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Other (+5.53% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCRX($1.75B) has a higher market cap than DVAX($1.62B) and TLSA($159M). TLSA YTD gains are higher at: 95.346 vs. BCRX (11.569) and DVAX (-15.270). BCRX has higher annual earnings (EBITDA): 12.8M vs. DVAX (9.67M) and TLSA (-17.14M). DVAX has more cash in the bank: 742M vs. BCRX (321M) and TLSA (201K). TLSA has less debt than DVAX and BCRX: TLSA (247K) vs DVAX (257M) and BCRX (809M). BCRX has higher revenues than DVAX and TLSA: BCRX (451M) vs DVAX (232M) and TLSA (0).
BCRXDVAXTLSA
Capitalization1.75B1.62B159M
EBITDA12.8M9.67M-17.14M
Gain YTD11.569-15.27095.346
P/E RatioN/A31.63N/A
Revenue451M232M0
Total Cash321M742M201K
Total Debt809M257M247K
FUNDAMENTALS RATINGS
BCRX vs DVAX vs TLSA: Fundamental Ratings
BCRX
DVAX
TLSA
OUTLOOK RATING
1..100
246434
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
70
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
645688
SMR RATING
1..100
1008496
PRICE GROWTH RATING
1..100
406336
P/E GROWTH RATING
1..100
10097100
SEASONALITY SCORE
1..100
n/a5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (31) in the Biotechnology industry is somewhat better than the same rating for DVAX (70) and is somewhat better than the same rating for TLSA (91). This means that BCRX's stock grew somewhat faster than DVAX’s and somewhat faster than TLSA’s over the last 12 months.

DVAX's Profit vs Risk Rating (56) in the Biotechnology industry is in the same range as BCRX (64) and is in the same range as TLSA (88). This means that DVAX's stock grew similarly to BCRX’s and similarly to TLSA’s over the last 12 months.

DVAX's SMR Rating (84) in the Biotechnology industry is in the same range as TLSA (96) and is in the same range as BCRX (100). This means that DVAX's stock grew similarly to TLSA’s and similarly to BCRX’s over the last 12 months.

TLSA's Price Growth Rating (36) in the Biotechnology industry is in the same range as BCRX (40) and is in the same range as DVAX (63). This means that TLSA's stock grew similarly to BCRX’s and similarly to DVAX’s over the last 12 months.

DVAX's P/E Growth Rating (97) in the Biotechnology industry is in the same range as TLSA (100) and is in the same range as BCRX (100). This means that DVAX's stock grew similarly to TLSA’s and similarly to BCRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXDVAXTLSA
RSI
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
78%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
N/A
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 19 days ago
80%
Bearish Trend 10 days ago
79%
Bearish Trend 19 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
77%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
BCRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DVAX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TLSA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DRTHX17.490.14
+0.81%
BNY Mellon Sustainable US Eq Fd Z
THORX37.650.04
+0.11%
Thornburg Global Opportunities R3
UEPIX16.17-0.02
-0.12%
ProFunds Europe 30 Inv
VVONX20.04-0.08
-0.40%
Invesco Value Opportunities R5
CAMYX27.81-0.14
-0.50%
Cambiar International Equity Instl

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
+2.07%
VCYT - BCRX
46%
Loosely correlated
+0.28%
OCGN - BCRX
44%
Loosely correlated
-2.40%
ETNB - BCRX
39%
Loosely correlated
+0.58%
DNLI - BCRX
38%
Loosely correlated
+1.23%
ARWR - BCRX
38%
Loosely correlated
-0.67%
More

DVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, DVAX has been loosely correlated with ACET. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if DVAX jumps, then ACET could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DVAX
1D Price
Change %
DVAX100%
-0.73%
ACET - DVAX
39%
Loosely correlated
-4.62%
SNDL - DVAX
35%
Loosely correlated
+0.68%
ALKS - DVAX
34%
Loosely correlated
+0.61%
SUPN - DVAX
33%
Loosely correlated
+2.78%
ETON - DVAX
29%
Poorly correlated
+0.19%
More

TLSA and

Correlation & Price change

A.I.dvisor tells us that TLSA and ALLK have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that TLSA and ALLK's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLSA
1D Price
Change %
TLSA100%
-5.56%
ALLK - TLSA
26%
Poorly correlated
N/A
ADTX - TLSA
24%
Poorly correlated
N/A
SAGE - TLSA
24%
Poorly correlated
N/A
AGIO - TLSA
23%
Poorly correlated
+0.65%
DARE - TLSA
22%
Poorly correlated
-0.50%
More